In vivo drug release behavior and osseointegration of a doxorubicin-loaded tissue-engineered scaffold

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


Bone tissue-engineered scaffolds with therapeutic effects must meet the basic requirements as to support bone healing at the defect side and to release an effect drug within the therapeutic window. Here, a rapid prototyped PCL scaffold embedded with chitosan/nanoclay/β-tricalcium phosphate composite (DESCLAYMR) loaded with chemotherapeutic drug doxorubicin (DESCLAYMR _DOX) is proposed as a potential multifunctional medical application for patients who undergo bone tumor resection. The DESCLAYMR_DOX scaffold can release DOX locally in a sustained manner in vivo without significantly increasing the plasma DOX concentrations. The evaluation of osseointegration showed increased mineralized bone formation, unmineralized collagen fibers and significantly higher alpha Smooth Muscle Actin (α-SMA) positive areas relative to total investigated area (TA) in defects treated solely with the DESCLAYMR scaffold than in the DESCLAYMR_DOX; and Alkaline phosphatase activity, α-SMA/TA and bone formation were higher in the DESCLAYMR loaded with 100 μg/scaffold DOX (DOX_low) than with 400 μg/scaffold DOX (DOX_high). Our results suggest that the DESCLAYMR_DOX can be a viable candidate as a multifunctional medical application by delivering the chemotherapeutic agent to target remaining tumor cells and facilitate bone formation.
Original languageEnglish
JournalRSC Advances
Pages (from-to)76237-76245
Number of pages9
Publication statusPublished - 8 Aug 2016

See relations at Aarhus University Citationformats

ID: 101949593